Copyright Reports & Markets. All rights reserved.

Global Transarterial Chemoembolization (TACE) Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Transarterial Chemoembolization (TACE) by Type
    • 1.3.1 Overview: Global Transarterial Chemoembolization (TACE) Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Transarterial Chemoembolization (TACE) Consumption Value Market Share by Type in 2025
    • 1.3.3 Chemotherapeutic Agents
    • 1.3.4 Radio Therapeutic Agents
    • 1.3.5 Drug-eluting Particles
    • 1.3.6 Others
  • 1.4 Global Transarterial Chemoembolization (TACE) Market by Application
    • 1.4.1 Overview: Global Transarterial Chemoembolization (TACE) Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospitals
    • 1.4.3 Clinics
    • 1.4.4 Cancer Research Centers
  • 1.5 Global Transarterial Chemoembolization (TACE) Market Size & Forecast
  • 1.6 Global Transarterial Chemoembolization (TACE) Market Size and Forecast by Region
    • 1.6.1 Global Transarterial Chemoembolization (TACE) Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Transarterial Chemoembolization (TACE) Market Size by Region, (2021-2032)
    • 1.6.3 North America Transarterial Chemoembolization (TACE) Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Transarterial Chemoembolization (TACE) Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Transarterial Chemoembolization (TACE) Market Size and Prospect (2021-2032)
    • 1.6.6 South America Transarterial Chemoembolization (TACE) Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Transarterial Chemoembolization (TACE) Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Questex
    • 2.1.1 Questex Details
    • 2.1.2 Questex Major Business
    • 2.1.3 Questex Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.1.4 Questex Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Questex Recent Developments and Future Plans
  • 2.2 Siemens Healthcare GmbH
    • 2.2.1 Siemens Healthcare GmbH Details
    • 2.2.2 Siemens Healthcare GmbH Major Business
    • 2.2.3 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.2.4 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Siemens Healthcare GmbH Recent Developments and Future Plans
  • 2.3 Bellicum Pharmaceuticals Inc.
    • 2.3.1 Bellicum Pharmaceuticals Inc. Details
    • 2.3.2 Bellicum Pharmaceuticals Inc. Major Business
    • 2.3.3 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.3.4 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Bellicum Pharmaceuticals Inc. Recent Developments and Future Plans
  • 2.4 Boston Scientific
    • 2.4.1 Boston Scientific Details
    • 2.4.2 Boston Scientific Major Business
    • 2.4.3 Boston Scientific Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.4.4 Boston Scientific Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Boston Scientific Recent Developments and Future Plans
  • 2.5 Cook Group
    • 2.5.1 Cook Group Details
    • 2.5.2 Cook Group Major Business
    • 2.5.3 Cook Group Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.5.4 Cook Group Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Cook Group Recent Developments and Future Plans
  • 2.6 Hikma Pharmaceuticals
    • 2.6.1 Hikma Pharmaceuticals Details
    • 2.6.2 Hikma Pharmaceuticals Major Business
    • 2.6.3 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.6.4 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Hikma Pharmaceuticals Recent Developments and Future Plans
  • 2.7 Nippon Kayaku
    • 2.7.1 Nippon Kayaku Details
    • 2.7.2 Nippon Kayaku Major Business
    • 2.7.3 Nippon Kayaku Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.7.4 Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Nippon Kayaku Recent Developments and Future Plans
  • 2.8 Novartis AG
    • 2.8.1 Novartis AG Details
    • 2.8.2 Novartis AG Major Business
    • 2.8.3 Novartis AG Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.8.4 Novartis AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Novartis AG Recent Developments and Future Plans
  • 2.9 Pfizer Inc.
    • 2.9.1 Pfizer Inc. Details
    • 2.9.2 Pfizer Inc. Major Business
    • 2.9.3 Pfizer Inc. Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.9.4 Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Pfizer Inc. Recent Developments and Future Plans
  • 2.10 Spectrum Pharmaceutical
    • 2.10.1 Spectrum Pharmaceutical Details
    • 2.10.2 Spectrum Pharmaceutical Major Business
    • 2.10.3 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.10.4 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Spectrum Pharmaceutical Recent Developments and Future Plans
  • 2.11 Roche Holding AG
    • 2.11.1 Roche Holding AG Details
    • 2.11.2 Roche Holding AG Major Business
    • 2.11.3 Roche Holding AG Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.11.4 Roche Holding AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Roche Holding AG Recent Developments and Future Plans
  • 2.12 Celgene
    • 2.12.1 Celgene Details
    • 2.12.2 Celgene Major Business
    • 2.12.3 Celgene Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.12.4 Celgene Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Celgene Recent Developments and Future Plans
  • 2.13 Bayer AG
    • 2.13.1 Bayer AG Details
    • 2.13.2 Bayer AG Major Business
    • 2.13.3 Bayer AG Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.13.4 Bayer AG Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Bayer AG Recent Developments and Future Plans
  • 2.14 Merck & Co., Inc.
    • 2.14.1 Merck & Co., Inc. Details
    • 2.14.2 Merck & Co., Inc. Major Business
    • 2.14.3 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.14.4 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Merck & Co., Inc. Recent Developments and Future Plans
  • 2.15 SingHealth
    • 2.15.1 SingHealth Details
    • 2.15.2 SingHealth Major Business
    • 2.15.3 SingHealth Transarterial Chemoembolization (TACE) Product and Solutions
    • 2.15.4 SingHealth Transarterial Chemoembolization (TACE) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 SingHealth Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Transarterial Chemoembolization (TACE) Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Transarterial Chemoembolization (TACE) by Company Revenue
    • 3.2.2 Top 3 Transarterial Chemoembolization (TACE) Players Market Share in 2025
    • 3.2.3 Top 6 Transarterial Chemoembolization (TACE) Players Market Share in 2025
  • 3.3 Transarterial Chemoembolization (TACE) Market: Overall Company Footprint Analysis
    • 3.3.1 Transarterial Chemoembolization (TACE) Market: Region Footprint
    • 3.3.2 Transarterial Chemoembolization (TACE) Market: Company Product Type Footprint
    • 3.3.3 Transarterial Chemoembolization (TACE) Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Transarterial Chemoembolization (TACE) Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Transarterial Chemoembolization (TACE) Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Transarterial Chemoembolization (TACE) Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Transarterial Chemoembolization (TACE) Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Transarterial Chemoembolization (TACE) Consumption Value by Type (2021-2032)
  • 6.2 North America Transarterial Chemoembolization (TACE) Market Size by Application (2021-2032)
  • 6.3 North America Transarterial Chemoembolization (TACE) Market Size by Country
    • 6.3.1 North America Transarterial Chemoembolization (TACE) Consumption Value by Country (2021-2032)
    • 6.3.2 United States Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Transarterial Chemoembolization (TACE) Consumption Value by Type (2021-2032)
  • 7.2 Europe Transarterial Chemoembolization (TACE) Consumption Value by Application (2021-2032)
  • 7.3 Europe Transarterial Chemoembolization (TACE) Market Size by Country
    • 7.3.1 Europe Transarterial Chemoembolization (TACE) Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 7.3.3 France Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Transarterial Chemoembolization (TACE) Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Transarterial Chemoembolization (TACE) Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Transarterial Chemoembolization (TACE) Market Size by Region
    • 8.3.1 Asia-Pacific Transarterial Chemoembolization (TACE) Consumption Value by Region (2021-2032)
    • 8.3.2 China Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 8.3.5 India Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Transarterial Chemoembolization (TACE) Consumption Value by Type (2021-2032)
  • 9.2 South America Transarterial Chemoembolization (TACE) Consumption Value by Application (2021-2032)
  • 9.3 South America Transarterial Chemoembolization (TACE) Market Size by Country
    • 9.3.1 South America Transarterial Chemoembolization (TACE) Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Transarterial Chemoembolization (TACE) Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Transarterial Chemoembolization (TACE) Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Transarterial Chemoembolization (TACE) Market Size by Country
    • 10.3.1 Middle East & Africa Transarterial Chemoembolization (TACE) Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Transarterial Chemoembolization (TACE) Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Transarterial Chemoembolization (TACE) Market Drivers
  • 11.2 Transarterial Chemoembolization (TACE) Market Restraints
  • 11.3 Transarterial Chemoembolization (TACE) Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Transarterial Chemoembolization (TACE) Industry Chain
  • 12.2 Transarterial Chemoembolization (TACE) Upstream Analysis
  • 12.3 Transarterial Chemoembolization (TACE) Midstream Analysis
  • 12.4 Transarterial Chemoembolization (TACE) Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Transarterial Chemoembolization (TACE) market size was valued at US$ 14000 million in 2025 and is forecast to a readjusted size of US$ 23940 million by 2032 with a CAGR of 8.1% during review period.
    Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.
    The global Transarterial Chemoembolization (TACE) market refers to the market for a minimally invasive procedure used in the treatment of liver cancer. TACE is a locoregional therapy that combines chemotherapy and embolization to deliver anticancer drugs directly to the tumor site while blocking the blood supply to the tumor.
    Liver cancer, specifically hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths worldwide. TACE has emerged as a commonly used treatment option for patients with intermediate-stage HCC or those who are not eligible for surgical resection or liver transplantation.
    The TACE procedure involves the insertion of a catheter into the hepatic artery, the main blood supply to the liver. Through the catheter, a drug-eluting bead or emulsion containing chemotherapeutic agents is infused directly into the tumor, followed by the injection of embolic agents to occlude the blood vessels feeding the tumor. This dual action targets the tumor cells and restricts their blood supply, thereby delaying tumor growth and potentially shrinking the tumor.
    Some key factors driving the global TACE market include:
    Increasing incidence of liver cancer: The rising prevalence of liver cancer, particularly HCC, has led to an increased demand for effective treatment options. TACE offers a targeted approach for patients with intermediate-stage HCC, who represent a significant portion of liver cancer cases.
    Limited surgical options: Liver resection and transplantation remain the most effective treatment options for early-stage HCC. However, many patients are not eligible for surgery due to the size and location of the tumor, underlying liver disease, or other patient factors. TACE provides a non-surgical alternative for these patients.
    Advancements in imaging and catheterization techniques: The advancements in imaging technologies, such as computed tomography (CT) and fluoroscopy, have improved the precision and safety of TACE procedures. Additionally, the development of better catheterization techniques and embolic agents has enhanced the effectiveness and outcomes of TACE.
    Multidisciplinary approach to cancer treatment: TACE is often used as part of a multidisciplinary approach to treating liver cancer. It may be combined with other interventions, such as radiofrequency ablation, sorafenib therapy, or immunotherapy, to achieve better treatment outcomes.
    The global TACE market includes various players, including medical device manufacturers, pharmaceutical companies, and healthcare providers offering TACE equipment, drugs, and related services. Additionally, research and development activities are continually focused on improving the effectiveness and safety of TACE procedures and developing innovative embolic agents and drug formulations.
    This report is a detailed and comprehensive analysis for global Transarterial Chemoembolization (TACE) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Transarterial Chemoembolization (TACE) market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Transarterial Chemoembolization (TACE) market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Transarterial Chemoembolization (TACE) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Transarterial Chemoembolization (TACE) market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Transarterial Chemoembolization (TACE)
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Transarterial Chemoembolization (TACE) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Questex, Siemens Healthcare GmbH, Bellicum Pharmaceuticals Inc., Boston Scientific, Cook Group, Hikma Pharmaceuticals, Nippon Kayaku, Novartis AG, Pfizer Inc., Spectrum Pharmaceutical, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Transarterial Chemoembolization (TACE) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Chemotherapeutic Agents
    Radio Therapeutic Agents
    Drug-eluting Particles
    Others
    Market segment by Application
    Hospitals
    Clinics
    Cancer Research Centers
    Market segment by players, this report covers
    Questex
    Siemens Healthcare GmbH
    Bellicum Pharmaceuticals Inc.
    Boston Scientific
    Cook Group
    Hikma Pharmaceuticals
    Nippon Kayaku
    Novartis AG
    Pfizer Inc.
    Spectrum Pharmaceutical
    Roche Holding AG
    Celgene
    Bayer AG
    Merck & Co., Inc.
    SingHealth
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Transarterial Chemoembolization (TACE) product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Transarterial Chemoembolization (TACE), with revenue, gross margin, and global market share of Transarterial Chemoembolization (TACE) from 2021 to 2026.
    Chapter 3, the Transarterial Chemoembolization (TACE) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Transarterial Chemoembolization (TACE) market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Transarterial Chemoembolization (TACE).
    Chapter 13, to describe Transarterial Chemoembolization (TACE) research findings and conclusion.

    Buy now